Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2014 16:05 ET | Source: Celsus Therapeutics

Celsus Therapeutics Provides Update on MRX-6 From FDA Pre-IND Meeting

Celsus completes Type B pre-IND meeting with FDA for MRX-6 cream in atopic dermatitis MRX-6 to advance into Phase II trials in US upon filing of IND expected in 4Q14 NEW YORK and LONDON,...
February 06, 2014 07:30 ET | Source: Celsus Therapeutics

Celsus Therapeutics to Present at the 2014 BIO CEO & Investor Conference

NEW YORK and LONDON, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief...
February 05, 2014 16:05 ET | Source: Celsus Therapeutics

Celsus Therapeutics Announces the Closing of $9.2 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional ADSs

NEW YORK and LONDON, Feb. 5, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the closing of its previously...
January 30, 2014 17:32 ET | Source: Celsus Therapeutics

Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ

NEW YORK and LONDON, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing...
October 24, 2013 08:15 ET | Source: Celsus Therapeutics

Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer

NEW YORK and LONDON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo Jimenez,...
October 21, 2013 08:15 ET | Source: Celsus Therapeutics

Celsus Therapeutics' MRX-6 Selected as One of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence

- MRX-6 is a Topical, Non-Steroidal Anti-Inflammatory Cream in Phase II Trials for Eczema - Celsus to present MRX-6 at Windover's Therapeutic Area Partnerships meeting NEW YORK and LONDON, Oct....
October 02, 2013 08:15 ET | Source: Celsus Therapeutics

Celsus Therapeutics Names Allan Shaw to Board of Directors

NEW YORK and LONDON, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today the addition of...
September 30, 2013 16:10 ET | Source: Celsus Therapeutics

Celsus Therapeutics Closes $12.5 Million Private Placement

NEW YORK and LONDON, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today that it has closed a...
September 19, 2013 08:21 ET | Source: Celsus Therapeutics

Celsus Therapeutics Announces $12.5 Million Private Placement

NEW YORK and LONDON, Sept. 19, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biotechnology company, announced today that it has entered into a...
September 17, 2013 07:00 ET | Source: Celsus Therapeutics

Celsus Therapeutics Announces ADR Ticker Symbol Change to CLSXY

NEW YORK and LONDON, Sept. 17, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biotechnology company, announced that effective September 16, 2013, the...